Blood test approved by FDA detects traumatic brain injuries

traumatic brain injuries

Blood test treats mild traumatic brain injuries

U.S. Food and Drug Administration approves a first blood test detects mild traumatic brain injuries (mTBI) or concussion in adults. The test, Banyan Brain Trauma Indicator, may reduce the people who exposed to radiation through CT scans that detect brain tissue damage or intracranial lesions.

If the blood test receive, it could wipe out the requirement for CT scans in at least a third of those with suspected brain injuries. According to the CDC, in 2013 nearly 50,000 people died due to TBI-related cases. TBI is caused by a head injury that interrupts with brain’s normal functioning. Its severity is very high, nearly 75 % of TBI cases occur each year.

Potential impacts of traumatic brain injuries

Mostly, patients with concussion have a negative CT scan. Potential impacts of TBI can include impaired thinking or memory, movement, sensation or emotional functioning.

Jeffrey Shuren, M.D., director of the FDA’s Center for Devices and Radiological Health, said, the new blood test is an important tool for the American public to help concussion evaluation.

Blood test measure proteins

The blood test measures the levels of UCH-L1 and GFAP proteins, release from the brain into the blood and measured within 12 hours of head injury. After a concussion, the protein levels can estimate patients who have intracranial lesions visible by CT scan and which won’t. The test results can available within 3 to 4 hours.

The FDA researchers assessed data from 1,947 individual adult blood samples with suspected mTBI/concussion and evaluated the performance of product by comparing CT scan results.

The Brain Trauma Indicator could predict the presence of intracranial lesions on a CT scan 97.5 percent of the time and those who did not have intracranial lesions on a CT scan 99.6 percent of the time. These findings demonstrate that the test can predict the absence of intracranial lesions.